Abstract

Investigation of Phosphodiesterase 5A (PDE5A) Inhibitors by Pharmacophore Modeling, Virtual Screening and Molecular Docking ApproachManish Sudesh Bhatia, Amol Shantinath Sherikar

Highlights

  • Phosphodiesterase type 5 inhibitors (PDE5i) are drugs used to treat erectile dysfunction of various etiologies in men

  • Red blood cells (RBC) count, haemoglobin (Hb) concentration, packed cell volume (PCV), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), red cell distribution wide standard deviation (RDW-SD), white blood cells (WBCs) count, platelets count, mean platelets volume (MPV) and platelets large cell ratio (PLCR) were significantly reduced in all the treated groups compared with the control

  • Platelet indices were poorly reversed in sildenafil and tramadol recovery groups

Read more

Summary

Introduction

Phosphodiesterase type 5 inhibitors (PDE5i) are drugs used to treat erectile dysfunction of various etiologies in men. Another study by Tas et al (2011) on sildenafil’s effect on haematological parameters in early phase of wound healing in diabetic rats revealed that, sildenafil played an important role in relieving the pressure on cellular activities and maintaining the wound healing within normal limits. Their findings showed that sildenafil administered to diabetic rats increased neutrophil and monocytes counts. Their findings showed that sildenafil had less aggregatory effects on platelets than tadalafil when used for the same duration of time. Nna et al (2015a) reported that sildenafil and tadalafil administered separately exhibited hyperlipidemic effects in male rats

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.